Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine

Background: Subjects with previous COVID-19 have augmented post-vaccination responses. However, the antibody response in COVID-naïve subjects from Southeast Asia is not well known. Methods: 77 COVID-naïve vaccinees were tested with a full antibody panel [spike antibodies (total (T-Ab), IgG, IgM) and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chin-Shern Lau, Soon Kieng Phua, Ya-Li Liang, Helen May-Lin Oh, Tar-Choon Aw
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 mRNA vaccines spike antibodies neutralizing antibodies Medicine R
Acceso en línea:	https://doaj.org/article/832be0fd0d2b48ddb2de017eb810ccaf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:832be0fd0d2b48ddb2de017eb810ccaf
record_format	dspace
spelling	oai:doaj.org-article:832be0fd0d2b48ddb2de017eb810ccaf2021-11-25T19:10:25ZRobust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine10.3390/vaccines91112412076-393Xhttps://doaj.org/article/832be0fd0d2b48ddb2de017eb810ccaf2021-10-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1241https://doaj.org/toc/2076-393XBackground: Subjects with previous COVID-19 have augmented post-vaccination responses. However, the antibody response in COVID-naïve subjects from Southeast Asia is not well known. Methods: 77 COVID-naïve vaccinees were tested with a full antibody panel [spike antibodies (total (T-Ab), IgG, IgM) and neutralizing antibodies (N-Ab)] pre-vaccination, 10 days after dose 1, and 20/40/60/90/120/150/180 days after dose 2. Results: 10 days after dose 1, 67.6% (48/71)/69.0% (49/71) were T-Ab/IgG positive; only 15.5% (11/71)/14.1% (10/71) were N-Ab/IgM positive. While all (100%) subjects had brisk T-Ab, IgG and N-Ab antibody responses 20 days after complete vaccination, only 79.1% (53/67) were IgM positive. At 180 days (<i>n</i> = 8), T-Ab/IgG/N-Ab were still reactive (lowest T-Ab 186 U/mL, IgG 617 AU/mL, N-Ab 0.39 µg/mL), but IgM was negative in all samples. Spike antibody thresholds of T-Ab 74.1 U/mL (r = 0.95) and IgG 916 AU/mL (r = 0.95) corresponded to N-Ab reactivity (>0.3 µg/mL). Non-linear regression analysis showed that N-Ab would decrease to 0.3 µg/mL by 241 days, whereas T-Ab/IgG would need 470/163 days to reach titers of T-Ab/IgG associated with a N-Ab 0.3 µg/mL (76.4 U/mL and 916 AU/mL respectively). Conclusions: The antibody responses of T-Ab, IgG and N-Ab remain high and durable even at 180 days. N-Ab titers are expected to remain reactive up to 241 days post-vaccination.Chin-Shern LauSoon Kieng PhuaYa-Li LiangHelen May-Lin OhTar-Choon AwMDPI AGarticleSARS-CoV-2mRNA vaccinesspike antibodiesneutralizing antibodiesMedicineRENVaccines, Vol 9, Iss 1241, p 1241 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 mRNA vaccines spike antibodies neutralizing antibodies Medicine R
spellingShingle	SARS-CoV-2 mRNA vaccines spike antibodies neutralizing antibodies Medicine R Chin-Shern Lau Soon Kieng Phua Ya-Li Liang Helen May-Lin Oh Tar-Choon Aw Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
description	Background: Subjects with previous COVID-19 have augmented post-vaccination responses. However, the antibody response in COVID-naïve subjects from Southeast Asia is not well known. Methods: 77 COVID-naïve vaccinees were tested with a full antibody panel [spike antibodies (total (T-Ab), IgG, IgM) and neutralizing antibodies (N-Ab)] pre-vaccination, 10 days after dose 1, and 20/40/60/90/120/150/180 days after dose 2. Results: 10 days after dose 1, 67.6% (48/71)/69.0% (49/71) were T-Ab/IgG positive; only 15.5% (11/71)/14.1% (10/71) were N-Ab/IgM positive. While all (100%) subjects had brisk T-Ab, IgG and N-Ab antibody responses 20 days after complete vaccination, only 79.1% (53/67) were IgM positive. At 180 days (<i>n</i> = 8), T-Ab/IgG/N-Ab were still reactive (lowest T-Ab 186 U/mL, IgG 617 AU/mL, N-Ab 0.39 µg/mL), but IgM was negative in all samples. Spike antibody thresholds of T-Ab 74.1 U/mL (r = 0.95) and IgG 916 AU/mL (r = 0.95) corresponded to N-Ab reactivity (>0.3 µg/mL). Non-linear regression analysis showed that N-Ab would decrease to 0.3 µg/mL by 241 days, whereas T-Ab/IgG would need 470/163 days to reach titers of T-Ab/IgG associated with a N-Ab 0.3 µg/mL (76.4 U/mL and 916 AU/mL respectively). Conclusions: The antibody responses of T-Ab, IgG and N-Ab remain high and durable even at 180 days. N-Ab titers are expected to remain reactive up to 241 days post-vaccination.
format	article
author	Chin-Shern Lau Soon Kieng Phua Ya-Li Liang Helen May-Lin Oh Tar-Choon Aw
author_facet	Chin-Shern Lau Soon Kieng Phua Ya-Li Liang Helen May-Lin Oh Tar-Choon Aw
author_sort	Chin-Shern Lau
title	Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
title_short	Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
title_full	Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
title_fullStr	Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
title_full_unstemmed	Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
title_sort	robust sars-cov-2 antibody responses in asian covid-naïve subjects 180 days after two doses of bnt162b2 mrna covid-19 vaccine
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/832be0fd0d2b48ddb2de017eb810ccaf
work_keys_str_mv	AT chinshernlau robustsarscov2antibodyresponsesinasiancovidnaivesubjects180daysaftertwodosesofbnt162b2mrnacovid19vaccine AT soonkiengphua robustsarscov2antibodyresponsesinasiancovidnaivesubjects180daysaftertwodosesofbnt162b2mrnacovid19vaccine AT yaliliang robustsarscov2antibodyresponsesinasiancovidnaivesubjects180daysaftertwodosesofbnt162b2mrnacovid19vaccine AT helenmaylinoh robustsarscov2antibodyresponsesinasiancovidnaivesubjects180daysaftertwodosesofbnt162b2mrnacovid19vaccine AT tarchoonaw robustsarscov2antibodyresponsesinasiancovidnaivesubjects180daysaftertwodosesofbnt162b2mrnacovid19vaccine
_version_	1718410226894372864

Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine

Ejemplares similares